Platelet activating factor receptor antagonists improve the efficacy of experimental chemo- and radiotherapy
Platelet activating factor is a lipid mediator of inflammation, and in recent decades, it has emerged as an important factor in tumor outcomes. Platelet activating factor acts by specific binding to its receptor, which is present in both tumor cells and cells that infiltrate tumors. Pro-tumorigenic...
Main Authors: | Ildefonso Alves da Silva Junior, Luciana Nogueira de Sousa Andrade, Sonia Jancar, Roger Chammas |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier España
2018-10-01
|
Series: | Clinics |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322018000200331&lng=en&tlng=en |
Similar Items
-
The Platelet-Activating Factor Receptor’s Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine
by: Eileen Deuster, et al.
Published: (2021-09-01) -
Impact of targeting the platelet-activating factor and its receptor in cancer treatment
by: Kimya Qaderi, et al.
Published: (2025-03-01) -
Re-Assessing the Role of Platelet Activating Factor and Its Inflammatory Signaling and Inhibitors in Cancer and Anti-Cancer Strategies
by: Alexandros Tsoupras, et al.
Published: (2024-09-01) -
Systematic Analysis of Two Tandem GGDEF/EAL Domain Genes Regulating Antifungal Activities in <i>Pseudomonas glycinae</i> MS82
by: Jinsheng Lin, et al.
Published: (2023-03-01) -
Modulation of inflammatory platelet-activating factor (PAF) receptor by the acyl analogue of PAF
by: Vyala Hanumanthareddy Chaithra, et al.
Published: (2018-11-01)